LXRX
LEXICON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.48
−0.34%Oct 29, 2026, 12:30 UTC
LEXICON PHARMACEUTICALS, INC. announced that it will release its third-quarter 2026 financial results before market open on November 5, 2026, and hold a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a business update.
Source:Oct 21, 2026, 12:30 UTC
LEXICON PHARMACEUTICALS, INC. highlighted findings from two newly reported preclinical studies showing favorable effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy and on platelet activity and thrombus formation.
Source:Aug 24, 2026, 12:30 UTC
Lexicon Pharmaceuticals earned a $10 million milestone payment from Novo Nordisk after achieving a key Phase 1 development milestone for LX9851, an oral non-incretin obesity candidate being developed by Novo Nordisk.
Source:Aug 6, 2026, 21:05 UTC
Lexicon Pharmaceuticals completed enrollment in its Phase III SONATA-HCM trial.
Source:Aug 6, 2026, 11:30 UTC
Lexicon Pharmaceuticals reported financial results for the second quarter of 2026.